[Experience of using reamberin on the cognitive functions in children with epilepsy]. / Opyt primeneniya reamberina dlya korrektsii kognitivnykh funktsii pri epilepsii u detei.

OBJECTIVE: To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the cognitive functions. MATERIAL AND METHODS: The study included 51 patients with epilepsy aged 7 to 15 years. The children were divided into four groups depending on the prescribed treatment. The first study group (n=16) received intravenous reamberin once daily for 5 days in addition to carbamazepine. The second group (n=15) received intravenous reamberin once daily for 5 days in addition to valproic acid. Two comparison groups (10 patients each) received only carbamazepine or only valproic acid, respectively. Cognitive functions were assessed at admission and on the 6th day of treatment using Schulte tables (10 words). RESULTS AND CONCLUSION: Reamberin significantly increases the work efficiency by 19-21%, and workability degree by 8-12% compared with the patients of the control groups. An analysis of the effect of succinate-containing drug on auditory memory has shown that the volumes of short-term memory and long-term memory are by 1.8 times and 1.3 times, respectively, higher than those in the control groups. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered clinically reasonable, and promising.

[The effect of reamberin on the antioxidant status in children with epilepsy]. / Primenenie reamberina dlia korrektsii antioksidantnogo statusa pri épilepsii u detei.

AIM: To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the antioxidant status. MATERIAL AND METHODS: The antioxidant activity of reamberin was investigated in children with epilepsy: 16 patients received intravenous reamberin once daily for 5 days in addition to carbamazepine. Patients of the control group (n=15) received only carbamazepine. The efficacy of the drug was evaluated by the levels of lipid hydroperoxides, conjugated dienes, and malondialdehyde and by the activity of the main components of the antioxidant system (ceruloplasmin, vitamin E, catalase) in the blood of patients. RESULTS AND CONCLUSION: Reamberin significantly reduces the plasma levels of lipid hydroperoxides by 16%, conjugated dienes by 12%, and malondialdehyde by 25% compared with the patients of the control group. An analysis of the effect of succinate-containing drugs on the activity of the antioxidant system components has shown that blood concentrations of ceruloplasmin, vitamin E and catalase are by 35, 14% and 15%, respectively, higher than those in the control group. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered pathogenetically justified, clinically reasonable, and promising.